Pharnext

Pharnext SA is a clinical-stage biopharmaceutical company based in Issy-Les-Moulineaux, France, specializing in the development of therapies for orphan and common neurodegenerative diseases. Founded in 2007 by prominent scientists and entrepreneurs, Pharnext employs a novel approach called PLEOTHERAPY, which uses network pharmacology and extensive genomic data to identify synergistic drug combinations from existing approved medications. Its leading products include SYNGILITY, which has successfully completed Phase III trials for Charcot-Marie-Tooth disease type 1A, and PXT864, which has shown promise in Phase II trials for Alzheimer’s disease, as well as in the treatment of Parkinson’s disease and amyotrophic lateral sclerosis. Pharnext also collaborates with the University Hospital Institute Mediterranee Infection to explore repurposed drugs for potential COVID-19 treatment. The company's innovative drug development strategy aims to provide effective and safe therapies while securing intellectual property through numerous granted patents.